A novel technique for measuring variations in DNA copy-number: competitive genomic polymerase chain reaction

Abstract

BackgroundChanges in genomic copy number occur in many human diseases including cancer. Characterization of these changes is important for both basic understanding and diagnosis of these diseases. Microarrays have recently become the standard technique and are commercially available. However, it is useful to have an affordable technique to complement them.ResultsWe describe a novel polymerase chain reaction (PCR)-based technique, termed competitive genomic PCR (CGP). The main characteristic of CGP is that different adaptors are added to the sample and control genomic DNAs after appropriate restriction enzyme digestion. These adaptor-supplemented DNAs are subjected to competitive PCR using an adaptor-primer and a locus-specific primer. The amplified products are then separated according to size differences between the adaptors. CGP eliminates the tedious steps inherent in quantitative PCR and achieves moderate throughput. Assays with different X chromosome numbers showed that it can provide accurate quantification. High-resolution analysis of neuroblastoma cell lines around the MYCN locus revealed novel junctions for amplification, which were not detected by a commercial array.ConclusionCGP is a moderate throughput technique for analyzing changes in genomic copy numbers. Because CGP can measure any genomic locus using PCR primers, it is especially useful for detailed analysis of a genomic region of interest.

Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers

“…7,8 With respect to predicting response to chemotherapy, Chang et al 9 reported on a diagnostic system using 92 genes for clinical response to docetaxel; whereas we reported a study of another such system using 85 genes that had similar diagnostic accuracy. 10 In addition, sequential taxane and anthracycline-containing regimes are used most commonly in the neoadjuvant setting. Thus, Ayers et al 11 tried to identify a 74-gene signature associated with pCR to sequential paclitaxel plus 5-fluorouracil (5-FU)/doxorubicin/cyclophosphamide (FAC), and Hess et al 12 reported using a 31-gene classifier as a predictor of pCR to the same regimen with similar diagnostic accuracy.…”

Accurate Measurement of the Relative Abundance of Different DNA Species in Complex DNA Mixtures

“…Many approaches including above two examples and others that are focused on defining copy number variation in the genomes are indeed capable of delineating the abundances of multiple sequences in the view of their relativity. 17 , 18 However, the accuracy and the precision that these approaches can confer are not as high as those our method can, or were not addressed probably due to disregard of presenting the relative abundances of intergenic sequences.…”

High-fidelity target sequencing of individual molecules identified using barcode sequences:de novodetection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients

“…The addition of an adaptor to a restriction enzyme site and the subsequent PCR amplification with an adaptor-primer and a single gene-specific primer constitute a robust technique that our group has extensively applied to genomic DNA 21 and RNA. 22 , 23 We have used this method for target sequencing with barcodes.…”